Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01461460 · ClinicalTrials.gov registry record · Phase 1
A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects
A Phase 1 study, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT01461460 is a Phase 1 study that has completed, run by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 48 participants.
The verdict
NCT01461460, a Phase 1 study, has completed, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effects of oral TR-701 free acid (FA) versus placebo on QTcF.
Interventions
- DRUG Placebo
- DRUG Moxifloxacin 400 mg
- DRUG TR-701 FA 1200 mg
- DRUG TR-701 FA 200 mg plus Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2011-11-28 |
| Est. Completion | 2011-12-23 |
| Phase | Phase 1 |
Sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)18 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01461460
The ClinicalTrials.gov registry entry for NCT01461460 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01461460 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01461460 about?
NCT01461460 is a clinical study titled "A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects". The purpose of this study is to assess the effects of oral TR-701 free acid (FA) versus placebo on QTcF.
What is the current status of trial NCT01461460?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2011-11-28. Estimated completion is 2011-12-23.
What interventions are being tested in trial NCT01461460?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin 400 mg (DRUG), TR-701 FA 1200 mg (DRUG), TR-701 FA 200 mg plus Placebo (DRUG).
Who is sponsoring clinical trial NCT01461460?
This trial is sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.